查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2049387

自體免疫疾病診斷市場規模、佔有率、趨勢和預測：按產品類型、疾病類型、檢測類型、最終用戶和地區分類，2026-2034年

Autoimmune Disease Diagnosis Market Size, Share, Trends and Forecast by Product Type, Disease Type, Test Type, End-User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3個工作天內

價格

2025年全球自體免疫疾病診斷市場規模為36億美元。展望未來，IMARC Group預測，該市場將在2026年至2034年間以5.35%的複合年成長率成長，到2034年達到58億美元。北美是該市場的主要驅動力，預計2025年將佔據超過39.7%的市場。對改善患者預後的日益關注、診斷技術的進步、主要公司之間的合作與夥伴關係，以及對精準診斷解決方案的需求，都是推動自體免疫疾病診斷市場成長的因素。

這個市場的成長主要受以下幾個關鍵因素驅動：類風濕性關節炎、狼瘡和多發性硬化症等自體免疫疾病在全球範圍內的發病率不斷上升，使得精準診斷的需求日益成長；患者和醫療專業人員對疾病的認知不斷提高，促使檢測和治療更加早期；生物標記發現和成像技術的進步，尤其能夠實現更快、更準確的檢測；人口老化加劇了自體免疫疾病的易感性，進一步刺激了市場需求；研發投入的增加推動了更先進診斷工具的研發；新興市場醫療基礎設施的不斷完善提高了檢測服務的可及性；此外，就地檢驗和檢查室自動化技術的普及縮短了檢測結果的報告時間，提高了診斷效率。這些因素共同推動了市場發展，並促進了各種診斷平台的創新。

在美國，透過新型多生物標記檢測，提高狼瘡和類風濕性關節炎等自體免疫疾病早期檢測率的工作正在加速推進。這些檢測工具旨在透過靶向TC4d、TIgG和TIgM等標記物來提高診斷靈敏度，這表明臨床免疫學領域正朝著更精準的血液檢測方向發展。例如，2025年1月，Exagen公司獲得了紐約州衛生部的有條件核准，其新型生物標記檢測將提高狼瘡和類風濕性關節炎的檢出能力。這些檢測計劃添加到AVISE CTD平台，旨在利用TC4d、TIgG和TIgM等生物標記來提高診斷靈敏度。

自體免疫疾病診斷市場的發展趨勢：

診斷技術的進步

新型生物標記，例如自體抗體，正被用於診斷特定的自體免疫疾病，如狼瘡、類風濕性關節炎和乳糜瀉。例如，流行病學研究表明，全球自體免疫疾病（新發病例）的年發病率正以每年19.1%的速度成長，而修格蘭氏症候群和狼瘡等風濕性疾病的年發病率也正以每年7.1%的速度成長。生物標記能夠更準確地對自體免疫疾病進行分類並實現早期檢測。蛋白質體學和代謝體學的進步使得個人化診斷成為可能，並有助於發現僅與自體免疫疾病相關的獨特蛋白質特徵和代謝譜。此外，微陣列技術能夠同時檢測多種生物標記物，從而更容易診斷涉及多種遺傳和蛋白質因素的複雜自體免疫疾病。同時，各公司不斷推出尖端產品和新技術，這對自體免疫疾病診斷市場的前景產生了積極影響。例如，2024年3月25日，艾伯維公司（AbbVie Inc.）和蘭多斯生物製藥公司（Landos Biopharma, Inc.）宣布達成最終協議，艾伯維將收購蘭多斯。蘭多斯是一家專注於開發治療自體免疫疾病的新型口服療法的臨床階段生物製藥公司。蘭多斯的主要候選藥物是NX-13，First-in-Class的口服NLRX1促效劑，具有雙峰作用機制（MOA）。

人們越來越關注改善患者治療效果。

2023年10月16日，美國食品藥物管理局（FDA）批准了Werfen公司Aptiva的510(k)上市核准，Aptiva是一種用於結締組織疾病（CTD）的重要試劑。這種新型試劑將有助於加速自體免疫疾病的診斷速度，並改善患者的治療效果，尤其對於那些難以診斷的疾病。根據對自體免疫自體免疫疾病診斷市場的預測，人們越來越重視早期準確檢測，以改善患者照護，這將推動市場需求。此外，早期診斷自體免疫疾病不僅能讓醫療專業人員迅速啟動治療，還能預防或延緩多發性硬化症、紅斑性狼瘡和類風濕性關節炎等疾病的發生。

大型公司之間的夥伴關係和夥伴關係

2023年1月10日，ScipherMedicine收購了位於費城的CrossBridge公司，後者是一家數據、分析和軟體供應商，此舉增強了ScipherMedicine自身的數據和分析能力。這將有助於更詳細、更即時地了解患者的治療路徑。這個基於價值的SaaS（軟體即服務）醫療保健平台將有助於降低醫療成本，同時改善患者的治療效果。透過各種合作，各公司正在整合其在免疫學、分子生物學和生物資訊學方面的專業知識，從而推動自體免疫疾病診斷市場的成長。許多製藥公司正與診斷公司合作，提供伴隨診斷測試，旨在識別最能從特定治療方法中受益的患者。例如，2025年4月，15項主要診斷測試總合進行了2,399,600次測試。與2024年4月相比，測試次數增加了70,600次（3.0%），若按運作調整，則增幅為8.2%。這些診斷方法有助於為自體免疫疾病患者配對最合適的生物製藥療法，從而改善治療效果，並減少治療方法選擇中的試驗。這些合作還包括聯合開發治療方法和診斷工具。例如，製藥公司可以與診斷公司合作開發用於監測治療效果的檢測方法，幫助醫生即時調整治療方法，進而改善患者的治療效果。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球自體免疫疾病診斷市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依產品類型分類

  • 耗材和檢測試劑盒
  • 裝置

第7章 市場區隔：依疾病類型分類

  • 系統性自體免疫疾病
    • 市場區隔：按類型
      • 類風濕性關節炎
      • 銀屑病
      • 全身性紅斑性狼瘡（SLE）
      • 多發性硬化症
      • 其他
  • 局部自體免疫疾病
    • 市場區隔：按類型
      • 發炎性腸道疾病
      • 1型糖尿病
      • 甲狀腺
      • 其他

第8章 市場區隔：依測試類型分類

  • 例行檢查
  • 發炎標記物
  • 自體抗體和免疫學檢測
  • 其他

第9章 市場區隔：依最終用戶分類

  • 臨床實驗室
  • 醫院
  • 其他

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Abbott Laboratories
    • AESKU.GROUP
    • Danaher Corp.
    • bioMerieux SA
    • Bio-Rad Laboratories Inc.
    • PerkinElmer Inc.
    • Hemagen Diagnostics, Inc.
    • Inova Diagnostics, Inc.
    • Myriad Genetics, Inc.
    • Quest Diagnostics Incorporated
    • Siemens Healthineers AG
    • SQI Diagnostics
    • Thermo Fisher Scientific Inc.
    • Trinity Biotech plc
Product Code: SR112026A2250

The global autoimmune disease diagnosis market size was valued at USD 3.6 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 5.8 Billion by 2034, exhibiting a CAGR of 5.35% during 2026-2034. North America dominated the market, holding a significant market share of over 39.7% in 2025. Rising focus on improving patient outcomes, advancements in diagnostic technologies, collaborations and partnerships among major players, and the need for accurate diagnostic solutions represent some of the factors contributing to the autoimmune disease diagnosis market share.

The market is growing due to several key drivers. The rising global incidence of autoimmune disorders like rheumatoid arthritis, lupus, and multiple sclerosis has increased the need for accurate diagnosis. Awareness among patients and healthcare providers has improved, prompting earlier testing and treatment. Technological advancements, especially in biomarker discovery and imaging, allow faster and more precise detection. Aging populations are more prone to autoimmune conditions, which further fuels demand. There's also increased investment in research and development, leading to better diagnostic tools. Expansion of healthcare infrastructure in emerging markets has improved access to testing services. In addition, the growing use of point-of-care testing and automation in labs helps reduce turnaround time, making diagnosis more efficient. These combined factors are pushing the market forward and encouraging innovation across diagnostic platforms.

In the United States, efforts to improve early detection of autoimmune disorders like lupus and rheumatoid arthritis are gaining pace through new multi-biomarker assays. These tools aim to raise diagnostic sensitivity by targeting markers such as TC4d, TIgG, and TIgM, signaling a shift toward more precise, blood-based testing methods in clinical immunology. For instance, in January 2025, Exagen Inc. received conditional approval from the New York State Department of Health for its new biomarker assays to enhance the detection of lupus and rheumatoid arthritis. The assays, set to be added to the AVISE CTD platform, were designed to improve diagnostic sensitivity using biomarkers like TC4d, TIgG, and TIgM.

AUTOIMMUNE DISEASE DIAGNOSIS MARKET TRENDS:

Advancements in Diagnostic Technologies

New biomarkers like autoantibodies are discovered to diagnose specific autoimmune diseases like lupus, rheumatoid arthritis, and celiac disease. For instance, epidemiological studies have shown that the incidence (rate of new cases) of global autoimmune diseases has risen yearly by 19.1% with rheumatological diseases such as Sjogren's and lupus rising 7.1% per year. Biomarkers can provide more precise classification and early identification of autoimmune diseases. More individualized diagnostics are allowing for the discovery of distinct protein signatures or metabolic profiles linked to autoimmune disorders only because of developments in proteomics and metabolomics. Furthermore, microarray technology allows simultaneous testing of multiple biomarkers, which makes it easier to diagnose complex autoimmune diseases involving multiple genetic or protein factors. Additionally, companies are launching cutting-edge products and new technologies, which is positively influencing the autoimmune disease diagnosis market outlook. For instance, on 25 March 2024 , AbbVie Inc. and Landos Biopharma, Inc. announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel and oral therapeutics for patients with autoimmune diseases. The main investigational asset of Landos is NX-13, a first-in-class, oral NLRX1 agonist with a bimodal mechanism of action (MOA).

Rising Focus on Improving Patient Outcomes

The US Food and Drug Administration (FDA) provided clearance for Werfen's Aptiva connective tissue disease (CTD) essential reagent under 510(k) on October 16, 2023. New reagents benefit in speeding up diagnosis and enhancing patient outcomes in difficult-to-diagnose autoimmune disorders. As per the autoimmune disease diagnosis market forecast, rising efforts to enhance early and precise detection for improved patient care are likely to boost demand. Apart from this, early diagnosis of autoimmune disorders enables medical professionals to start treatment quickly while preventing or delaying the onset of diseases, including multiple sclerosis, lupus, and rheumatoid arthritis.

Collaborations and Partnerships among Key Players

On January 10, 2023, ScipherMedicine acquired CrossBridge, a Philadelphia-based data, analytics, and software company, to enhance its data and analytics capabilities. This enables a more granular and real time understanding of patients' treatment pathways. The software as a service (SaaS) value-based care platform aids in lowering healthcare costs while enhancing patient outcomes. Through various collaborations, companies combine their expertise in immunology, molecular biology, and bioinformatics, which supports the autoimmune disease diagnosis market growth. A large number of pharmaceutical companies are collaborating with diagnostic companies to provide companion diagnostics tests that are intended to determine which patients will benefit the most from particular treatments. For instance, in total 2,399,600 of the 15 key diagnostic tests were performed during April 2025. This is an increase of 70,600 (3.0%) from April 2024, which is 8.2% when adjusted for working days. These diagnostics aid in matching patients with the best biologic therapy for autoimmune illnesses, enhancing results while decreasing treatment selection trial and error. These partnerships also involve the co-development of treatments and diagnostic tools. For instance, pharmaceutical companies might work with diagnostics firms to create tests that monitor treatment efficacy, helping doctors adjust therapies in real time to improve patient outcomes.

AUTOIMMUNE DISEASE DIAGNOSIS INDUSTRY SEGMENTATION:

Analysis by Product Type:

  • Consumables and Assay Kits
  • Instruments

Consumables and assay kits stood as the largest product type in 2025, holding around 72.8% of the market. Diagnostic laboratories and hospitals require a continuous supply of consumables and assay kits for routine testing and monitoring of autoimmune diseases. Since autoimmune conditions often require long-term monitoring, the demand for consumables remains high. They are used in a variety of diagnostic procedures, including immunohistochemistry, flow cytometry, Western blot, and enzyme-linked immunosorbent assay (ELISA). They play a vital role in identifying autoantibodies connected to celiac disease, multiple sclerosis, lupus, and rheumatoid arthritis. Assay kits and consumables have a shorter lifespan as compared to diagnostic devices.

Analysis by Disease Type:

  • Systemic Autoimmune Disease
    • Rheumatoid Arthritis
    • Psoriasis
    • Systemic Lupus Erythematosus (SLE)
    • Multiple Sclerosis
    • Others
  • Localized Autoimmune Disease
    • Inflammatory Bowel Disease
    • Type 1 Diabetes
    • Thyroid
    • Others

Localized autoimmune disease led the market with around 51.7% of market share in 2025. Localized autoimmune diseases are far more common as compared to systemic autoimmune illnesses. Localized autoimmune disease diagnostic procedures are more precise and targeted. Additionally, companies are developing products that aid in the treatment of various illnesses. For example, on June 9, 2023, AstraZeneca and Quell Therapeutics entered in a license agreement to develop multiple engineered T-regulator (Treg) cell therapies with the potential to be curative for both type 1 diabetes (T1D) and inflammatory bowel disease (IBD) indications. Autologous multi-modular Treg cell therapy candidates for key autoimmune disease indications will be developed using Quell's patented toolbox of Treg cell engineering modules. This is expected to provide a positive autoimmune disease diagnosis market forecast.

Analysis by Test Type:

  • Routine Laboratory Tests
  • Inflammatory Markers
  • Autoantibodies and Immunologic Tests

Autoantibodies and immunologic tests led the market with around 35.3% of market share in 2025. The growing use of autoantibodies and immunologic tests is pushing demand in the autoimmune disease diagnosis market. These tests help detect early-stage autoimmune disorders by identifying specific autoantibodies linked to diseases like rheumatoid arthritis, lupus, and type 1 diabetes. Their accuracy makes them a preferred first-line diagnostic tool among clinicians. With more awareness, patients are seeking earlier evaluation, especially when symptoms are vague. Labs and diagnostics companies are expanding panels to include newer biomarkers, which are now being validated at a faster rate due to advances in immunology. Also, insurance coverage for these tests has improved, reducing out-of-pocket costs and encouraging broader adoption. As autoimmune conditions become more widely recognized and better understood, the use of immunologic assays continues to increase, helping drive both clinical demand and revenue in this segment.

Analysis by End-User:

  • Clinical Laboratories
  • Hospitals

Hospitals led the market with around 53.6% of market share in 2025. In the autoimmune disease diagnosis market, hospitals are a major demand driver due to their role as primary diagnostic and treatment centers. They handle a large share of autoimmune cases, especially moderate to severe ones that require specialized testing. Hospitals typically invest in advanced diagnostic tools, such as autoantibody panels, ANA testing, and flow cytometry, because of the need for accuracy in complex cases. These facilities often house multidisciplinary teams, including immunologists, rheumatologists, and lab technicians, who rely on high-throughput and integrated diagnostic systems. The increasing number of autoimmune disorders being diagnosed in hospital settings, combined with a rise in hospital-based outpatient services, also adds to the volume. Further, hospitals tend to adopt newer diagnostic technologies earlier than small labs or clinics, which helps boost market growth through faster adoption and higher procurement volumes.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 39.7%. North America, particularly the United States, has a high prevalence of autoimmune diseases among individuals. The region benefits from a highly developed healthcare system with widespread access to advanced diagnostic technologies. Clinical laboratories, hospitals, and specialized diagnostic centers have the latest molecular diagnostics and imaging techniques, enabling efficient and accurate diagnosis of autoimmune diseases. Besides this, autoimmune disease diagnosis companies in the region are focusing on introducing solutions that provide enhanced care to individuals suffering from autoimmune diseases. For example, on October 03, 2023, WellTheory, a first-of-its-kind virtual solution for the 50 Million Americans suffering from autoimmune disease, launched an enterprise solution that will enable employers and payers to offer autoimmune care through WellTheory. Through its new enterprise solution, WellTheory will be able to tackle the unseen costs and productivity impacts of untreated autoimmune diseases across the entire healthcare ecosystem.

KEY REGIONAL TAKEAWAYS:

UNITED STATES AUTOIMMUNE DISEASE DIAGNOSIS MARKET ANALYSIS

In 2025, the United States accounted for 91.50% of the market share in North America. United States is witnessing increased autoimmune disease diagnosis adoption due to the sharp rise of autoimmune diseases across various age groups. Over 50 Million Americans (8% of the U.S. population) are affected by autoimmune diseases and current data suggests that the prevalence of autoimmune diseases is rising. The growing prevalence of conditions such as multiple sclerosis and rheumatoid arthritis has prompted healthcare providers to invest in advanced testing tools. The rise of autoimmune diseases has created pressure on public health systems, leading to enhanced diagnostic programs and early intervention strategies. Hospitals and clinics are emphasizing personalized diagnostics, which is accelerating the adoption of specialized screening tools. Growing awareness, availability of advanced diagnostic technologies, and integration of electronic health records further support early detection. In addition, insurance coverage for autoimmune disease-related tests has improved access to diagnosis. Rising clinical research initiatives are also contributing to the adoption of advanced autoimmune disease diagnosis tools nationwide.

ASIA PACIFIC AUTOIMMUNE DISEASE DIAGNOSIS MARKET ANALYSIS

Asia-Pacific is experiencing growing autoimmune disease diagnosis adoption primarily due to the increasing number of Type 1 Diabetes patients. For instance, the estimated number of individuals with diabetes in India was 32 Million in the year 2000, which rose to 63 Million by 2012, 74 Million in 2021, and it is now 101 Million, according to the ICMR-INDIAB Study. This autoimmune disorder, commonly diagnosed in children and young adults, has seen a notable surge across urban and semi-urban populations. The rising incidence of Type 1 Diabetes is prompting significant investments in early diagnostic platforms, with a focus on improving glycemic control and disease monitoring. Healthcare systems are expanding their diagnostic infrastructure to manage growing pediatric and adolescent cases. The increase in Type 1 Diabetes patients is also driving innovation in test kits, especially those supporting rapid and accurate detection.

EUROPE AUTOIMMUNE DISEASE DIAGNOSIS MARKET ANALYSIS

Europe is seeing a rising prevalence of thyroid-related autoimmune disorders, particularly Hashimoto's thyroiditis and Graves' disease, which is leading to greater reliance on diagnostic technologies. Expansion of healthcare infrastructure across urban and rural areas is improving access to advanced autoimmune disease diagnostic services. For instance, Germany has more than 1,900 hospitals, including over 30 elite university hospitals, combining top-level patient care with research and innovation. Public health campaigns targeting thyroid awareness and increased physician focus on autoimmune symptoms are enhancing early detection. New investments in immunology labs and academic research centres are aiding diagnosis accuracy. Technological upgrades in laboratories and clinical support systems are boosting adoption further. Rising healthcare expenditure and the aging population are also contributing to broader diagnosis initiatives. With growing thyroid cases and investment on healthcare infrastructure in Europe, the region continues to strengthen its position in autoimmune disease diagnostics.

LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSIS MARKET ANALYSIS

Latin America is witnessing increased autoimmune disease diagnosis adoption driven by rising incidences of lupus, rheumatoid arthritis, and celiac disease. Awareness campaigns and support from medical societies are prompting early clinical consultations. Expanding diagnostic facilities and greater availability of trained professionals are improving accessibility. For instance, Novo Nordisk plans to invest USD 1.09 Billion to boost Ozempic, Wegovy production in Brazil. As autoimmune diseases like lupus, rheumatoid arthritis, and celiac disease gain attention, diagnostic procedures are becoming more widespread. Rising focus on public healthcare support is contributing to enhanced diagnosis practices.

MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASE DIAGNOSIS MARKET ANALYSIS

Middle East and Africa are undergoing rapid improvements in healthcare systems, leading to broader autoimmune disease diagnosis adoption. Growing healthcare facilities are increasing the availability of diagnostics in both urban and semi-urban areas. For the 2025 fiscal year, the UAE allocated AED 5.7 Billion, equivalent to 8% of the federal budget, to healthcare and community prevention services, reflecting its sustained commitment to developing the health sector. With more hospitals and laboratories being equipped for autoimmune screenings, patients now have better access to early-stage diagnostics. Expansion of medical infrastructure continues to support effective diagnosis in the region.

COMPETITIVE LANDSCAPE:

The autoimmune disease diagnostics market is seeing steady activity across product development, research, and collaborations. Diagnostic tools are becoming more precise, with new technologies enabling earlier and less invasive detection. Research groups and labs are working closely with diagnostics firms to bring innovations into clinical use more quickly. AI and machine learning are starting to influence test development, especially in pattern recognition and predictive diagnostics. Governments are showing more interest through national health strategies and dedicated funding for autoimmune conditions. Product launches and R&D remain the most consistent forms of progress, while formal partnerships and agreements are also frequent. Compared to others, large-scale fundraising or private investment announcements are less common right now. Most movement is driven by research and collaboration.

The report provides a comprehensive analysis of the competitive landscape in the autoimmune disease diagnosis market with detailed profiles of all major companies, including:

  • Abbott Laboratories
  • AESKU.GROUP
  • Danaher Corp.
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • PerkinElmer Inc.
  • Hemagen Diagnostics, Inc.
  • Inova Diagnostics, Inc.
  • Myriad Genetics, Inc.
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • SQI Diagnostics
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech plc

Key Questions Answered in This Report

1. How big is the autoimmune disease diagnosis market?

2. What is the future outlook of autoimmune disease diagnosis market?

3. What are the key factors driving the autoimmune disease diagnosis market?

4. Which region accounts for the largest autoimmune disease diagnosis market share?

5. Which are the leading companies in the global autoimmune disease diagnosis market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Autoimmune Disease Diagnosis Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Consumables and Assay Kits
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Instruments
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Systemic Autoimmune Disease
    • 7.1.1 Market Trends
    • 7.1.2 Market Breakup by Type
      • 7.1.2.1 Rheumatoid Arthritis
      • 7.1.2.2 Psoriasis
      • 7.1.2.3 Systemic Lupus Erythematosus (SLE)
      • 7.1.2.4 Multiple Sclerosis
      • 7.1.2.5 Others
    • 7.1.3 Market Forecast
  • 7.2 Localized Autoimmune Disease
    • 7.2.1 Market Trends
    • 7.2.2 Market Breakup by Type
      • 7.2.2.1 Inflammatory Bowel Disease
      • 7.2.2.2 Type 1 Diabetes
      • 7.2.2.3 Thyroid
      • 7.2.2.4 Others
    • 7.2.3 Market Forecast

8 Market Breakup by Test Type

  • 8.1 Routine Laboratory Tests
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Inflammatory Markers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Autoantibodies and Immunologic Tests
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Clinical Laboratories
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Hospitals
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AESKU.GROUP
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Danaher Corp.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 bioMerieux SA
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Bio-Rad Laboratories Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 PerkinElmer Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Hemagen Diagnostics, Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Inova Diagnostics, Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Myriad Genetics, Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Quest Diagnostics Incorporated
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Siemens Healthineers AG
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
    • 14.3.12 SQI Diagnostics
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
    • 14.3.13 Thermo Fisher Scientific Inc.
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis
    • 14.3.14 Trinity Biotech plc
      • 14.3.14.1 Company Overview
      • 14.3.14.2 Product Portfolio
      • 14.3.14.3 Financials
      • 14.3.14.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Autoimmune Disease Diagnosis Market: Major Drivers and Challenges
  • Figure 2: Global: Autoimmune Disease Diagnosis Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Autoimmune Disease Diagnosis Market: Breakup by Product Type (in %), 2025
  • Figure 4: Global: Autoimmune Disease Diagnosis Market: Breakup by Disease Type (in %), 2025
  • Figure 5: Global: Autoimmune Disease Diagnosis Market: Breakup by Test Type (in %), 2025
  • Figure 6: Global: Autoimmune Disease Diagnosis Market: Breakup by End-User (in %), 2025
  • Figure 7: Global: Autoimmune Disease Diagnosis Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 9: Global: Autoimmune Disease Diagnosis (Consumables and Assay Kits) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Autoimmune Disease Diagnosis (Consumables and Assay Kits) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Autoimmune Disease Diagnosis (Instruments) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Autoimmune Disease Diagnosis (Instruments) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Autoimmune Disease Diagnosis (Systemic Autoimmune Disease) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Autoimmune Disease Diagnosis (Systemic Autoimmune Disease) Market: Breakup by Disease Type (in %), 2025
  • Figure 15: Global: Autoimmune Disease Diagnosis (Systemic Autoimmune Disease) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Autoimmune Disease Diagnosis (Localized Autoimmune Disease) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Autoimmune Disease Diagnosis (Localized Autoimmune Disease) Market: Breakup by Disease Type (in %), 2025
  • Figure 18: Global: Autoimmune Disease Diagnosis (Localized Autoimmune Disease) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Autoimmune Disease Diagnosis (Routine Laboratory Tests) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Autoimmune Disease Diagnosis (Routine Laboratory Tests) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Autoimmune Disease Diagnosis (Inflammatory Markers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Autoimmune Disease Diagnosis (Inflammatory Markers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Autoimmune Disease Diagnosis (Autoantibodies and Immunologic Tests) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Autoimmune Disease Diagnosis (Autoantibodies and Immunologic Tests) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Autoimmune Disease Diagnosis (Other Test Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Autoimmune Disease Diagnosis (Other Test Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Autoimmune Disease Diagnosis (Clinical Laboratories) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Autoimmune Disease Diagnosis (Clinical Laboratories) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Autoimmune Disease Diagnosis (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Autoimmune Disease Diagnosis (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Autoimmune Disease Diagnosis (Other End-Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Autoimmune Disease Diagnosis (Other End-Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: North America: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: North America: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: United States: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: United States: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Canada: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Canada: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Asia Pacific: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Asia Pacific: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: China: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: China: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Japan: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Japan: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: India: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: India: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: South Korea: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: South Korea: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Australia: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Australia: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Indonesia: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Indonesia: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Others: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Others: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Europe: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Europe: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Germany: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Germany: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: France: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: France: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: United Kingdom: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: United Kingdom: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Italy: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Italy: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Spain: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Spain: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Russia: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Russia: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Others: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Others: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Latin America: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Latin America: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Brazil: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Brazil: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Mexico: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Mexico: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Others: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Others: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Middle East and Africa: Autoimmune Disease Diagnosis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Middle East and Africa: Autoimmune Disease Diagnosis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Global: Autoimmune Disease Diagnosis Industry: SWOT Analysis
  • Figure 82: Global: Autoimmune Disease Diagnosis Industry: Value Chain Analysis
  • Figure 83: Global: Autoimmune Disease Diagnosis Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Autoimmune Disease Diagnosis Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Autoimmune Disease Diagnosis Market Forecast: Breakup by Product Type (in Million USD), 2026-2034
  • Table 3: Global: Autoimmune Disease Diagnosis Market Forecast: Breakup by Disease Type (in Million USD), 2026-2034
  • Table 4: Global: Autoimmune Disease Diagnosis Market Forecast: Breakup by Test Type (in Million USD), 2026-2034
  • Table 5: Global: Autoimmune Disease Diagnosis Market Forecast: Breakup by End-User (in Million USD), 2026-2034
  • Table 6: Global: Autoimmune Disease Diagnosis Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Autoimmune Disease Diagnosis Market Structure
  • Table 8: Global: Autoimmune Disease Diagnosis Market: Key Players